Psoriasis News

The National Psoriasis Foundation dedicated August to psoriasis education, awareness and education, designating it Psoriasis Action Month.

Tildrakizumab exhibited real-world efficacy and safety for long-term treatment of plaque psoriasis, according to a study.

In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.

The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has announced.

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

In patients with early and complete clearance of psoriasis, extending the guselkumab dosing interval to every 16 weeks maintained disease control as well as an 8-week interval, according to a study published in JAMA Dermatology.

Patients and clinicians agree that as-needed use of biologic therapy has benefits over continuous long-term biologic use for the treatment of psoriasis, according to a study.

Patients treated with interleukin-23i or IL-12/23i for psoriasis exhibited similar rates of risk for developing psoriatic arthritis, according to a study.

The European Commission has granted marketing authorization for two devices that administer Bimzelx for the treatment of multiple inflammatory diseases, UCB announced in a press release.

Poor representation of darker skin tones in dermatology training materials has led to delayed diagnoses and worse treatment outcomes in Black, Asian and non-white Latin American patients, according to a presenter.